Is TRLV a Buy or a Sell? The Bull and Bear Case (2026)

Last updated July 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Trulieve Cannabis (TRLV) rests on Schedule III ends 280E for the medical business: A Justice Department and DEA final order moved state-licensed medical marijuana from Schedule I to Schedule III with effect in late April 2026. The bear case rests on cannabis is still a federally controlled substance. Analysts covering it publish targets from $15.00 to $21.00 against a $11.69 price, so even the professionals disagree by 33% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

Trulieve Cannabis Corp., headquartered in Tallahassee, Florida, runs roughly ~207 medical dispensaries backed by about ~3.5 million square feet of cultivation and processing capacity, with retail accounting for roughly ~94% of revenue. Its operating footprint is Florida, Georgia, Pennsylvania and West Virginia, with conditional licenses in Alabama and Texas. On June 3, 2026 the company restructured and deconsolidated Harvest, the arm holding its mixed medical and adult-use markets (Arizona, Connecticut, Maryland and Ohio, about ~34 dispensaries), keeping roughly ~90% of the economics but none of the operational control. That left a medical-only entity that could meet NYSE listing standards, and the subordinate voting shares moved from the Canadian Securities Exchange (TRUL) and OTCQX (TCNNF) to the NYSE under TRLV on June 10, 2026. A redomicile from British Columbia to Delaware completed on August 11, 2026. The financial picture is a profitable retail operation carrying an unresolved federal tax dispute. Revenue over the trailing twelve months was about ~$1.14 billion, down roughly ~4%, and second-quarter revenue of about ~$271 million was down roughly ~10% year over year, of which about ~$222 million came from the medical-only business that continues into the third quarter. Gross margin held near ~60% and adjusted EBITDA margin near ~36%, and the company ended June with about ~$325 million of cash against roughly ~$289 million of debt at about ~9.6%. The large reported net loss is a non-cash artifact of the Harvest deconsolidation charge rather than trading performance. What sits underneath the whole story is roughly ~$598 million of uncertain tax position liabilities tied largely to Section 280E, alongside a share price that has already climbed roughly ~36% in a month against a 52-week range of about ~$4.62 to ~$13.28.

The bull case: what would have to be true for $21.00

The most optimistic published target on TRLV is $21.00, +79.6% from the $11.69 price as of September 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Schedule III ends 280E for the medical business

A Justice Department and DEA final order moved state-licensed medical marijuana from Schedule I to Schedule III with effect in late April 2026. Section 280E disallows ordinary deductions only for Schedule I and II businesses, so Trulieve's medical operations stop being taxed on gross profit and start being taxed on actual income. That single change is the largest swing factor in the company's cash earnings, and it showed up as roughly ~$20.4 million of adjusted net income in the second quarter.

2. A major-exchange listing and a US domicile

Listing on the NYSE on June 10, 2026 and completing the British Columbia to Delaware redomicile on August 11, 2026 removed two structural filters that had kept most institutional mandates out of the name: an OTC quote and a foreign corporate domicile. The company also authorized a share repurchase program of up to about ~$50 million. Whether index inclusion and broader ownership follow is the open question rather than the listing itself.

3. Florida density plus newer medical states

Florida remains the profit engine, and the roughly ~207 store base is now supplemented by expansion in Georgia and Pennsylvania and conditional licenses in Alabama and Texas. Management guided third-quarter revenue to be comparable with the second quarter's medical-only figure of about ~$222 million, with Georgia and Pennsylvania growth offsetting the usual seasonal Florida softness. Growth from here looks like new-state ramp rather than same-store acceleration.

4. The retained Harvest economics

Trulieve still holds roughly ~90% of the economics in Harvest, carried at about ~$152.5 million under the equity method, covering Arizona, Connecticut, Maryland and Ohio. Adult-use exposure therefore sits outside the consolidated operating entity. If federal treatment of adult-use cannabis shifts at the DEA hearing that opened in June 2026, that value would reach shareholders as equity income and a potential re-consolidation question rather than as reported revenue today.

The bear case: what would have to be true for $15.00

The most pessimistic published target is $15.00, +28.3% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Trulieve Cannabis is worth if the risks below bite instead of the drivers above.

Cannabis is still a federally controlled substance. Rescheduling moved state-licensed medical marijuana to Schedule III effective in April 2026, which ends the Section 280E deduction disallowance for Trulieve's medical operations prospectively, but it does not legalize the drug, does not open interstate commerce, and does not resolve prior tax years. The company carries roughly ~$598 million of uncertain tax position liabilities tied largely to 280E, has already collected about ~$113 million in refunds on amended returns the IRS is contesting, and concluded that its own position does not meet the ASC 740 recognition threshold for tax years before 2026, so a clawback is a genuine possibility rather than a theoretical one. Operationally, second-quarter revenue fell roughly ~10% year over year, and Florida adult-use legalization is dead for the 2026 ballot after the state Supreme Court declined to revive a signature challenge in March 2026, removing the catalyst that had driven the prior two years of the story. The shares have already risen roughly ~36% in a month toward the top of their 52-week range, which means an investor is paying for a favorable regulatory outcome that the DEA has not yet delivered.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding TRLV already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on TRLV

7 analysts cover TRLV, with an average target of $18.18 (+55.5% against $11.69) and a split of 7 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the TRLV forecast and price target page.

How is TRLV valued? (as of September 2026)

Price

$11.69

Market cap

$2.25B

Forward P/E

21.04

Price / book

1.93

Beta

1.72

52-week range

$4.62 to $13.28

Snapshot for TRLV as of September 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$1.14 billion, down ~4% year over year
Q2 2026 revenue: ~$271 million, of which ~$222 million was medical-only
Adjusted EBITDA (H1 2026): ~$198 million at a ~36% margin
Market capitalization: ~$2.25 billion at ~$11.69 per share
Price to sales (TTM): ~2.0x
Balance sheet: ~$325 million cash against ~$289 million debt at ~9.6%

Reported GAAP earnings are not usable as a valuation input this year, because the trailing net loss of roughly ~$473 million is dominated by a non-cash charge of about ~$403 million from the Harvest deconsolidation; adjusted net income was about ~$20.4 million in the second quarter. At roughly ~2x trailing sales the multiple looks modest for a ~60% gross margin retailer, though the forward revenue base is the medical-only run rate of about ~$890 million rather than the trailing ~$1.14 billion. Seven analysts covering the stock carry an average twelve-month price target near ~$18, which prices in retroactive 280E relief that has not been granted.

How do you decide if TRLV is a buy?

Rather than asking whether TRLV is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold TRLV indirectly through an index or sector ETF before adding more.

What would change your mind on TRLV

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Schedule III ends 280E for the medical business stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: cannabis is still a federally controlled substance fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the TRLV stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about TRLV against your real portfolio and see your actual exposure before deciding.

Investing in Trulieve Cannabis with AI

Connect the broker you already use and ask Walnut's AI how TRLV fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does TRLV fit me?

FAQ

Is TRLV a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Schedule III ends 280E for the medical business, with revenue (ttm) at ~$1.14 billion, down ~4% year over year. The bear case rests on cannabis is still a federally controlled substance. Analysts covering it are spread from $15.00 to $21.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell TRLV?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Cannabis is still a federally controlled substance. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $15.00, +28.3% from the $11.69 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for TRLV?

Schedule III ends 280E for the medical business. A Justice Department and DEA final order moved state-licensed medical marijuana from Schedule I to Schedule III with effect in late April 2026. The most optimistic analyst target on TRLV is $21.00, +79.6% from the $11.69 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for TRLV?

What does Trulieve Cannabis do?

Trulieve Cannabis is a US medical cannabis operator anchored in Florida, running roughly 207 dispensaries backed by about 3.5 million square feet of growing capacity.

What would have to change for TRLV to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Schedule III ends 280E for the medical business) stalling in the reported numbers rather than in the narrative, the risk above (cannabis is still a federally controlled substance) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

How can I invest in TRLV?

TRLV trades on the New York Stock Exchange, so it can be held in an ordinary US brokerage account without the OTC or Canadian-market workarounds that plant-touching cannabis stocks previously required. Many brokers restricted or blocked cannabis names while they were OTC-quoted, and the NYSE listing removes that friction at most firms.

What exchange is TRLV listed on, and what was it before?

The subordinate voting shares began trading on the NYSE under TRLV at the open on June 10, 2026. Before that the company traded on the Canadian Securities Exchange under TRUL and on OTCQX under TCNNF, both of which stopped at the close on June 9, 2026. The NYSE listing is the primary one today.

Why can Trulieve list on the NYSE when other US cannabis operators cannot?

Two things had to happen. State-licensed medical marijuana was rescheduled from Schedule I to Schedule III with effect in late April 2026, and on June 3, 2026 Trulieve deconsolidated Harvest, the arm holding its mixed medical and adult-use markets. The listed entity therefore touches only federally rescheduled medical cannabis.

Walnut is informational, not investment advice, and gives no verdict on TRLV. Analyst targets referenced here come from a September 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.